Our results support the idea that metoprolol counteracts the detrimental effects of hyperglycemia by coupling a direct mechanism, such as the selective β1-AR antagonist, that could participate in ERK1/2 activation in HG conditions. The gene discussed is MAPK3; the disease is Hyperglycemia.